Innovative retatrutide, a combined-action drug targeting equally GLP-1 and GIP receptors, is sparking considerable interest within the medical community. Preliminary clinical studies have revealed substantial decreases in overall mass and gains in health markers for individuals with overweight. Researchers believe this ground-breaking approach cou